Tenaya Therapeutics (TNYA) Price & Analysis

Compare

2,782 Followers

TNYA Stock Chart & Stats

$1.26

-$0.05(-3.69%)

At close: Jan 08 4:00 PM EST

$1.26

-$0.05(-3.69%)

Day’s Range― - ―

52-Week Range$0.36 - $4.01

Previous CloseN/A

Volume1.07M

Average Volume (3M)4.19M

Market Cap

$224.91M

Enterprise Value$40.04M

Total Cash (Recent Filing)$56.31M

Total Debt (Recent Filing)$11.53M

Price to Earnings (P/E)―

Beta2.74

Next Earnings

Mar 24, 2026

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding162,976,100

10 Day Avg. Volume5,920,511

30 Day Avg. Volume4,191,660

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.31

Price to Sales (P/S)0.00

P/FCF Ratio-1.33

Enterprise Value/Market Cap0.18

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-10.14

Enterprise Value/Ebitda-0.46

Forecast

1Y Price Target

$11.33

Price Target Upside799.21% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Biomarker ImprovementsCardiac biomarkers show positive trends in most patients.

Clinical Trial ProgressInterim Ph1b/2a results for TN-201 indicate benefits improve over time with early signs of a meaningful dose response.

Safety And TolerabilitySafety data for all patients showed that TN-201 was generally well tolerated at both doses, with no dose-limiting toxicities observed.

Bears Say

Cash RunwayYears of cash left is approximately 0.9, indicating limited financial runway.

Clinical Hold ImpactThe FDA placed TN-201 on clinical hold due to the need for protocolized patient monitoring and immunosuppression regimen.

Financial ConcernsTenaya reported a loss of $20.3 million for the third quarter of 2025.

Tenaya Therapeutics News

Tenaya Therapeutics reports Q3 EPS (12c), consensus (15c)

“Throughout the third quarter, we made important steps advancing our two lead gene therapy programs to provide transformative...

9d ago

TNYA

Tenaya Therapeutics presents new interim safety, efficacy data on TN-201

Tenaya Therapeutics (TNYA) announced that new interim safety and efficacy data from the company’s MyPEAK-1 Phase 1b/2a clinical...

10d ago

TNYA

Tenaya Therapeutics management to meet with Piper Sandler

Meeting to be held in New York on October 22 hosted by Piper Sandler. Published first on TheFly...

29d ago

TNYA

Tenaya Therapeutics Reports Improved Financials Amid Strategic Focus

Tenaya Therapeutics, Inc. ( ($TNYA) ) has released its Q3 earnings. Here is a breakdown of the information...

8d ago

TNYA

Promising Outlook for Tenaya Therapeutics’ TN-201 Program Despite Procedural Clinical Hold

LifeSci Capital analyst Cory Jubinville, PhD reiterated a Buy rating on Tenaya Therapeutics today and set a price...

9d ago

TNYA

Promising Clinical Developments and Regulatory Optimism Drive Buy Rating for Tenaya Therapeutics

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Tenaya Therapeutics, retaining the price target of...

9d ago

TNYA

FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial

The latest announcement is out from Tenaya Therapeutics ( ($TNYA) ). The FDA has placed a clinical hold...

12d ago

TNYA

Promising Developments in Tenaya Therapeutics’ MyPEAK-1 Study Support Buy Rating

Tenaya Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD...

15d ago

TNYA

Tenaya Therapeutics Advances Genetic Therapy for Heart Disease: A Closer Look at the TN-201 Study

Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Tenaya Therapeutics, Inc. is conducting a...

23d ago

TNYA

Tenaya Therapeutics Advances Gene Therapy Study for ARVC

Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Tenaya Therapeutics, Inc. is conducting a...

23d ago

TNYA

Tenaya Therapeutics Advances Pediatric Cardiomyopathy Research with New Study Update

Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Study Overview: The study titled A...

23d ago

TNYA

Tenaya Therapeutics’ ARVC Study: A Closer Look at AAV9 Antibody Prevalence

Tenaya Therapeutics, Inc. (($TNYA)) announced an update on their ongoing clinical study. Tenaya Therapeutics, Inc. is conducting a...

23d ago

TNYA

Promising Developments and Strategic Approaches in Tenaya Therapeutics’ Gene Therapy Programs Drive Buy Rating

Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics and keeping the price target...

3M ago

TNYA

Tenaya Therapeutics presents interim data from MyClimb natural history study

Tenaya Therapeutics (TNYA) announced the presentation of interim data from its ongoing MyClimb natural history study of pediatric...

3M ago

TNYA

TNYA FAQ

What was Tenaya Therapeutics’s price range in the past 12 months?

Tenaya Therapeutics lowest stock price was $0.36 and its highest was $4.01 in the past 12 months.

What is Tenaya Therapeutics’s market cap?

Tenaya Therapeutics’s market cap is $224.91M.

When is Tenaya Therapeutics’s upcoming earnings report date?

Tenaya Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 125 days.

How were Tenaya Therapeutics’s earnings last quarter?

Tenaya Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.148 by $0.028.

Is Tenaya Therapeutics overvalued?

According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenaya Therapeutics pay dividends?

Tenaya Therapeutics does not currently pay dividends.

What is Tenaya Therapeutics’s EPS estimate?

Tenaya Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does Tenaya Therapeutics have?

Tenaya Therapeutics has 162,976,100 shares outstanding.

What happened to Tenaya Therapeutics’s price movement after its last earnings report?

Tenaya Therapeutics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.148. Following the earnings report the stock price went up 11.719%.

Which hedge fund is a major shareholder of Tenaya Therapeutics?

Currently, no hedge funds are holding shares in TNYA

Tenaya Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-96.44%

Trailing 12-Months

Asset Growth

-25.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenaya Therapeutics

Tenaya Therapeutics (TNYA) is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company operates within the biopharmaceutical sector and is committed to advancing a pipeline of novel therapies aimed at addressing the underlying causes of various forms of heart disease through gene therapy, cellular regeneration, and precision medicine approaches.

Tenaya Therapeutics (TNYA) Earnings & Revenues

Historic Earnings Reports

TNYA Stock 12 Month Forecast

Average Price Target

$11.33

▲(799.21% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","-1":"-$1","9.5":"$9.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,9.5,20,30.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,4.406153846153846,7.372307692307693,10.338461538461539,13.304615384615385,16.270769230769233,19.23692307692308,22.203076923076924,25.169230769230772,28.13538461538462,31.101538461538464,34.067692307692305,37.033846153846156,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,2.2007692307692306,2.9615384615384617,3.7223076923076923,4.483076923076924,5.243846153846155,6.004615384615384,6.765384615384615,7.526153846153846,8.286923076923078,9.047692307692309,9.80846153846154,10.569230769230769,{"y":11.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.44,1.56,1.68,1.8,1.92,2.04,2.16,2.2800000000000002,2.4,2.52,2.64,2.76,2.88,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >